{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:33:32Z","timestamp":1787016812716,"version":"build-2736575974"},"reference-count":33,"publisher":"BMJ","issue":"9","funder":[{"name":"UCSD Jacobs Retina Center","award":["Unrestricted"],"award-info":[{"award-number":["Unrestricted"]}]},{"name":"NIH","award":["5R01EY033847"],"award-info":[{"award-number":["5R01EY033847"]}]},{"name":"NIH","award":["R01EY016323"],"award-info":[{"award-number":["R01EY016323"]}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["Unrestricted"],"award-info":[{"award-number":["Unrestricted"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Bridge2AI"],"award-info":[{"award-number":["Bridge2AI"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["OT2OD032644"],"award-info":[{"award-number":["OT2OD032644"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSD Vision Research Center Core Grant","award":["P30EY022589"],"award-info":[{"award-number":["P30EY022589"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,4,24]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To determine the effect of continuing anti-vascular endothelial growth factor (VEGF) injections on the progression of macular atrophy (MA) during remission of neovascular age-related macular degeneration (nAMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, 59 eyes with nAMD with at least 6-month remission (disease inactivity) were analysed and were grouped into two. In group 1, anti-VEGF injections were stopped after remission (holiday). In group 2, injections were continued despite inactivity (maintenance).<\/jats:p>\n                    <jats:p>Using blue autofluorescence images via Heidelberg Spectralis, MA area was measured at initial injection, remission onset and the latest available remission point. The absence of subretinal haemorrhage, intraretinal fluid, subretinal fluid or subretinal hyper-reflective material associated with fluid on serial spectral domain optical coherence tomography scans was used to confirm the inactivity of the disease (remission). The rate of progression of MA during the period of remission was measured for the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In group 1, 30 eyes received a mean of 16.97 injections over 39.2 months, followed by 21 months of drug holiday. In group 2, 29 eyes received a mean of 27.1 injections over 62.16 months, followed by a mean of 11.59 injections over 19.32 months for maintenance. The MA in the maintenance group progressed faster than the holiday group during remission (p=0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maintenance injections for nAMD in remission significantly increase progression of MA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2024-326124","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T05:24:48Z","timestamp":1747718688000},"page":"1028-1035","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-VEGF injections and macular atrophy progression in patients with neovascular age-related macular degeneration in remission"],"prefix":"10.1136","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4653-2021","authenticated-orcid":false,"given":"Nehal Nailesh","family":"Mehta","sequence":"first","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"},{"name":"Viterbi Family Department of Ophthalmology at the Shiley Eye Institute, University of California, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-6764","authenticated-orcid":false,"given":"Ines Doris","family":"Nagel","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"},{"name":"Viterbi Family Department of Ophthalmology at the Shiley Eye Institute, University of California, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4624-8250","authenticated-orcid":false,"given":"Akshay","family":"Agnihotri","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-2272","authenticated-orcid":false,"given":"Fritz Gerald Paguiligan","family":"Kalaw","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7115-8767","authenticated-orcid":false,"given":"Anna","family":"Heinke","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-5173","authenticated-orcid":false,"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"},{"name":"Viterbi Family Department of Ophthalmology at the Shiley Eye Institute, University of California, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-8708","authenticated-orcid":false,"given":"Dirk-Uwe","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"},{"name":"Viterbi Family Department of Ophthalmology at the Shiley Eye Institute, University of California, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-2500","authenticated-orcid":false,"given":"William R","family":"Freeman","sequence":"additional","affiliation":[{"name":"Ophthalmology, UCSD, San Diego, California, USA"},{"name":"Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA"},{"name":"Viterbi Family Department of Ophthalmology at the Shiley Eye Institute, University of California, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025082002151088000_109.9.1028.1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"2025082002151088000_109.9.1028.2","doi-asserted-by":"crossref","unstructured":"Waugh N , Loveman E , Colquitt J , et al . Chapter 1, introduction to age-related macular degeneration. In: Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Southampton (UK): NIHR Journals Library, 2018. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500483\/","DOI":"10.3310\/hta22270"},{"key":"2025082002151088000_109.9.1028.3","first-page":"15","article-title":"Current terminology for geographic atrophy pathology: efforts aim to dispel confusion as potential treatments approach","volume":"20","author":"Jaffe","year":"2023","journal-title":"Retin Physician"},{"key":"2025082002151088000_109.9.1028.4","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.318"},{"key":"2025082002151088000_109.9.1028.5","first-page":"786870","article-title":"Anti-VEGF Treatment Strategies for NAMD","volume":"113","author":"Kovach","year":"2006","journal-title":"J Ophthalmol"},{"key":"2025082002151088000_109.9.1028.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025082002151088000_109.9.1028.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"2025082002151088000_109.9.1028.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702938"},{"key":"2025082002151088000_109.9.1028.9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002998"},{"key":"2025082002151088000_109.9.1028.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.05.008"},{"key":"2025082002151088000_109.9.1028.11","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.208"},{"key":"2025082002151088000_109.9.1028.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.015"},{"key":"2025082002151088000_109.9.1028.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.06.025"},{"key":"2025082002151088000_109.9.1028.14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001059"},{"key":"2025082002151088000_109.9.1028.15","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003207"},{"key":"2025082002151088000_109.9.1028.16","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v16i2.9081"},{"key":"2025082002151088000_109.9.1028.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04404-0"},{"key":"2025082002151088000_109.9.1028.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"2025082002151088000_109.9.1028.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"2025082002151088000_109.9.1028.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.09.028"},{"key":"2025082002151088000_109.9.1028.21","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.7.6.40"},{"key":"2025082002151088000_109.9.1028.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.12.002"},{"key":"2025082002151088000_109.9.1028.23","first-page":"338","article-title":"Risk factors associated with incident geographic atrophy in age-related macular degeneration","volume":"122","author":"Chew","year":"2015","journal-title":"Ophthalmology"},{"key":"2025082002151088000_109.9.1028.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.11.023"},{"key":"2025082002151088000_109.9.1028.25","article-title":"Topographic Variation of the Growth Rate of Geographic Atrophy in Nonexudative Age-Related Macular Degeneration: A Systematic Review and Meta-analysis","volume":"61","author":"Shen","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2025082002151088000_109.9.1028.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.028"},{"key":"2025082002151088000_109.9.1028.27","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8353"},{"key":"2025082002151088000_109.9.1028.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"key":"2025082002151088000_109.9.1028.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.033"},{"key":"2025082002151088000_109.9.1028.30","unstructured":"Friedlander MF . VEGF antagonism-can you have too much of a good thing? presented at: angiogenesis, exudation, and degeneration 2013. Miami; 2013."},{"key":"2025082002151088000_109.9.1028.31","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01766-6"},{"key":"2025082002151088000_109.9.1028.32","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1111\/aos.13157","article-title":"Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration","volume":"94","author":"Munk","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"2025082002151088000_109.9.1028.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.04.031"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-326124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T09:15:35Z","timestamp":1755681335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-326124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,20]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bjo-2024-326124"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-326124","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}